header
Maine Medicine Weekly E-Update, July 20, 2022

In This Issue
MAINE MEDICINE WEEKLY UPDATE
July 20, 2022
LEAD STORIES
Monkeypox Now a Reportable Condition in Maine
Federal COVID-19 Public Health Emergency Extended
Novavax COVID-19 Vaccine Authorized by FDA & CDC
Maine Joins National Launch Of 988 Suicide And Crisis Lifeline
MORE CDC NEWS
Recent Reports of Human Parechovirus (PeV) in the United States
PHYSICIANS IN THE NEWS
Maine Physicians Direct Primacy Care Model to Improve Medical Care
LEGISLATIVE ADVOCACY
MMA Government Affairs Developing 2023-2024 State Legislative Agenda
SUBSTANCE USE DISORDER
CDC Launches New Addiction Medicine Toolkit
Revised Narcotic Treatment Program Manual
Governor Mills Hosts 4th Annual Opioid Response Summit
COVID CORNER
Concerns About BA.5 Variants Contagiousness, Hospitalizations
MMA'S ANNUAL MEETING
Sign Up Now for the MMA 169th Annual Session in Bar Harbor!
CANCER CARE
ASGE Colon Cancer Appropriate Screening Test Campaign
AWARD NOMINATIONS
Nominations Due by July 29 for 2022 Mary Cushman, MD Award
UPCOMING EVENTS
Upcoming Specialty Society Meetings
HEALTHCARE EMPLOYMENT OPPORTUNITIES
Island Physician - MD/DO
Family Medicine Physician - Penobscot Community Health Care’s Brewer Medical Center
Physician
Thoracic Surgeon Opportunity at Progressive Medical Center in Maine
Lead Hematology/Oncology Opportunity in Northern Maine
Experienced Emergency Medicine PA Opportunity in Bangor, Maine!

 
Search Back Issues



 

 

 

 

 

 


Follow Us:
Novavax COVID-19 Vaccine Authorized by FDA & CDC

The Food and Drug Administration (FDA) last week approved an emergency use authorization (EUA) for the Novavax COVID-19 vaccine, bringing a fourth vaccine to help against the backdrop of a BA.5 Omicron subvariant surge and lagging vaccine and booster dose uptake.

Earlier this week, Centers for Disease Control and Prevention Director Rochelle Walensky endorsed the Novavax COVID-19 vaccine following a 12-0 vote recommending the traditional protein-based shot by the agency's Advisory Committee on Immunization Practices (ACIP). Novavax's vaccine will hit the market in the coming weeks.

Emergency use of the Novavax COVID-19 vaccine is for individuals 18 years of age and older. The vaccine is authorized for emergency use as a two-dose primary series, given three weeks apart.

The vaccine will be permitted to be given to adults as a primacy immunization series, limiting its use given roughly two-thirds of people have already received their initial shots. However, the vaccine may be a good option for those allergic to components of the messenger RNA vaccines developed by Pfizer-BioNTech and Moderna.

The Biden administration has bought 3.5 million doses of the vaccine, which is administered in a two-dose series given 3 to 8 weeks apart. Those with moderate or severe immune compromise should receive the doses 3 weeks apart.

For More Information

Fact Sheet for Recipients and Caregivers

Fact Sheet for Healthcare Providers Administering Vaccine

Advisory Meeting Webcast

< Previous Article | Next Article >

[ return to top ]

To ensure delivery of Maine Medicine Weekly Update,
please add 'info@mainemed.com' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details: http://www.commpartners.com/website/white-listing.htm


Unsubscribe here

For more information or to contact us directly, please visit www.mainemed.com | ©